Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2020 Q2- Text added to 2020 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
New words:
adequacy, Avastin, Baker, bevacizumab, Biomedical, biosimilar, CAB, Chamber, colorectal, counterclaim, device, earned, endorsed, EO, EOs, GD, Hand, HGRAC, highest, Hillhouse, HSCI, ICC, Junior, LP, margin, mechanism, Minsheng, month, NDRL, payback, recover, repurchase, rulemaking, Seng, sovereignty, stronger, transformation, twelve, upgrade, VBP, vigorously, wave, widespread, Zhaohui, Zhuhai
Valuein 2020 Q2 filing- Value in 2020 Q3 filing
Original filings
Filing view